01472: Enhanced Killing of Malignant Histiocytosis with a Novel Combination of Anti-Tumor Drugs

Grant Status: Closed

Grant Amount: $57,526
Steven W. Dow, DVM, PhD; Colorado State University
January 1, 2011 - December 31, 2013

Sponsor(s): American Maltese Association, Boston Terrier Club of America, Miniature Pinscher Club of America, Inc., Papillon Club of America, Pug Dog Club of America, Inc., Yorkshire Terrier Club of America

Breed(s): Bernese Mountain Dog, Rottweiler, Flat-Coated Retriever, Golden Retriever
Research Program Area: Oncology
Donate to Support this Research Program Area

Project Summary

The studies supported by this CHF grant sought to determine whether the combination of liposomal clodronate, a macrophage depleting agent, and CCNU, a chemotherapy drug, were more effective in treating canine malignant histiosarcoma than either agent alone. The studies found that the combination of both drugs together was not significantly more effective than either alone, though there was a trend towards better long-term survival in dogs treated with both agents. A larger study would be required to more fully address this question. Thus, there remains an unmet need for new treatments to more effectively manage MH in dogs.

Publication(s)

Hafeman, S. D., Varland, D., & Dow, S. W. (2012). Bisphosphonates significantly increase the activity of doxorubicin or vincristine against canine malignant histiocytosis cells. Veterinary and Comparative Oncology, 10(1), 44–56. https://doi.org/10.1111/j.1476-5829.2011.00274.x

Help Future Generations of Dogs

Participate in canine health research by providing samples or by enrolling in a clinical trial. Samples are needed from healthy dogs and dogs affected by specific diseases.

Learn How to Help

Make an Investment Today:

  • $50
  • $100
  • $250
  • $1000
  • Give Now
Connect With Us:
Get Canine Health News:
Please leave this field empty

© 2018 AKC Canine Health Foundation | Privacy Policy | Site Map

Site by Blackbaud, Inc.

Powered by Blackbaud
nonprofit software